This is a good law for India, because they have the capability to manufacture medicine, while lacking the capability to invent them. It's one of the many ways the world freeloads on U.S. medical R&D spending.
("This admission reflects the view that Indian drug companies are finding it difficult to develop successful new molecules. Discovering new drugs requires huge investment, and has not been favourably looked upon by risk-averse Indian investors. Several Indian molecules have failed in the clinic, including Piramal’s head and neck cancer candidate P276 in 2012. Even the antimalarial Synriam (arterolane and piperaquine), which Ranbaxy hailed as India’s first domestically developed drug, was originally discovered elsewhere.")
